approval · primary record
RAVULIZUMAB-CWVZ
FDA · BLA · 2026-10-21
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2026-10-21 |
| Approval events | 1 |
| Brand | ULTOMIRIS |
| Sponsor | ALEXION PHARM |
| Route | INJECTION |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-10-21 | FDA | BLA | ULTOMIRIS | ALEXION PHARM | INJECTION |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:31:21.083Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:ravulizumab-cwvz
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ravulizumab-Cwvz · compound